PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders

Andrew Siderowf, Michael J. Pontecorvo, Holly A. Shill, Mark A. Mintun, Anupa Arora, Abhinay D. Joshi, Ming Lu, Charles Howard Adler, Douglas Galasko, Carolyn Liebsack, Daniel M. Skovronsky, Marwan N. Sabbagh

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Biomarkers based on the underlying pathology of Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB) have the potential to improve diagnosis and understanding of the substrate for cognitive impairment in these disorders. The objective of this study was to compare the patterns of amyloid and dopamine PET imaging in patients with AD, DLB and Parkinson's disease (PD) using the amyloid imaging agent florbetapir F 18 and 18F-AV-133 (florbenazine), a marker for vesicular monamine type 2 transporters (VMAT2).Methods: Patients with DLB and AD, Parkinson's disease (PD) and healthy controls (HC) were recruited for this study. On separate days, subjects received intravenous injections of florbetapir, and florbenazine. Amyloid burden and VMAT2 density were assessed quantitatively and by binary clinical interpretation. Imaging results for both tracers were compared across the four individual diagnostic groups and for combined groups based on underlying pathology (AD/DLB vs. PD/HC for amyloid burden and PD/DLB vs. AD/HC for VMAT binding) and correlated with measures of cognition and parkinsonism.Results: 11 DLB, 10 AD, 5 PD, and 5 controls participated in the study. Amyloid binding was significantly higher in the combined AD/DLB patient group (n = 21) compared to the PD/HC groups (n = 10, mean SUVr: 1.42 vs. 1.07; p = 0.0006). VMAT2 density was significantly lower in the PD/DLB group (n = 16) compared to the AD/ HC group (n = 15; 1.83 vs. 2.97; p < 0.0001). Within the DLB group, there was a significant correlation between cognitive performance and striatal florbenazine binding (r = 0.73; p = 0.011).Conclusions: The results of this study show significant differences in both florbetapir and florbenazine imaging that are consistent with expected pathology. In addition, VMAT density correlated significantly with cognitive impairment in DLB patients (ClinicalTrials.gov identifier: NCT00857506, registered March 5, 2009).

Original languageEnglish (US)
Article number79
JournalBMC Neurology
Volume14
Issue number1
DOIs
StatePublished - Apr 9 2014

Fingerprint

Lewy Bodies
Amyloid
Dopamine
Alzheimer Disease
Lewy Body Disease
Parkinson Disease
Pathology
florbetapir
florbenazine F 18
Corpus Striatum
Control Groups
Parkinsonian Disorders
Intravenous Injections
Cognition
Dementia
Biomarkers

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Parkinson's disease
  • PET imaging

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. / Siderowf, Andrew; Pontecorvo, Michael J.; Shill, Holly A.; Mintun, Mark A.; Arora, Anupa; Joshi, Abhinay D.; Lu, Ming; Adler, Charles Howard; Galasko, Douglas; Liebsack, Carolyn; Skovronsky, Daniel M.; Sabbagh, Marwan N.

In: BMC Neurology, Vol. 14, No. 1, 79, 09.04.2014.

Research output: Contribution to journalArticle

Siderowf, A, Pontecorvo, MJ, Shill, HA, Mintun, MA, Arora, A, Joshi, AD, Lu, M, Adler, CH, Galasko, D, Liebsack, C, Skovronsky, DM & Sabbagh, MN 2014, 'PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders', BMC Neurology, vol. 14, no. 1, 79. https://doi.org/10.1186/1471-2377-14-79
Siderowf, Andrew ; Pontecorvo, Michael J. ; Shill, Holly A. ; Mintun, Mark A. ; Arora, Anupa ; Joshi, Abhinay D. ; Lu, Ming ; Adler, Charles Howard ; Galasko, Douglas ; Liebsack, Carolyn ; Skovronsky, Daniel M. ; Sabbagh, Marwan N. / PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. In: BMC Neurology. 2014 ; Vol. 14, No. 1.
@article{4042abbc76b7442792e76cec7bc7ed2a,
title = "PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders",
abstract = "Background: Biomarkers based on the underlying pathology of Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB) have the potential to improve diagnosis and understanding of the substrate for cognitive impairment in these disorders. The objective of this study was to compare the patterns of amyloid and dopamine PET imaging in patients with AD, DLB and Parkinson's disease (PD) using the amyloid imaging agent florbetapir F 18 and 18F-AV-133 (florbenazine), a marker for vesicular monamine type 2 transporters (VMAT2).Methods: Patients with DLB and AD, Parkinson's disease (PD) and healthy controls (HC) were recruited for this study. On separate days, subjects received intravenous injections of florbetapir, and florbenazine. Amyloid burden and VMAT2 density were assessed quantitatively and by binary clinical interpretation. Imaging results for both tracers were compared across the four individual diagnostic groups and for combined groups based on underlying pathology (AD/DLB vs. PD/HC for amyloid burden and PD/DLB vs. AD/HC for VMAT binding) and correlated with measures of cognition and parkinsonism.Results: 11 DLB, 10 AD, 5 PD, and 5 controls participated in the study. Amyloid binding was significantly higher in the combined AD/DLB patient group (n = 21) compared to the PD/HC groups (n = 10, mean SUVr: 1.42 vs. 1.07; p = 0.0006). VMAT2 density was significantly lower in the PD/DLB group (n = 16) compared to the AD/ HC group (n = 15; 1.83 vs. 2.97; p < 0.0001). Within the DLB group, there was a significant correlation between cognitive performance and striatal florbenazine binding (r = 0.73; p = 0.011).Conclusions: The results of this study show significant differences in both florbetapir and florbenazine imaging that are consistent with expected pathology. In addition, VMAT density correlated significantly with cognitive impairment in DLB patients (ClinicalTrials.gov identifier: NCT00857506, registered March 5, 2009).",
keywords = "Alzheimer's disease, Biomarkers, Parkinson's disease, PET imaging",
author = "Andrew Siderowf and Pontecorvo, {Michael J.} and Shill, {Holly A.} and Mintun, {Mark A.} and Anupa Arora and Joshi, {Abhinay D.} and Ming Lu and Adler, {Charles Howard} and Douglas Galasko and Carolyn Liebsack and Skovronsky, {Daniel M.} and Sabbagh, {Marwan N.}",
year = "2014",
month = "4",
day = "9",
doi = "10.1186/1471-2377-14-79",
language = "English (US)",
volume = "14",
journal = "BMC Neurology",
issn = "1471-2377",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders

AU - Siderowf, Andrew

AU - Pontecorvo, Michael J.

AU - Shill, Holly A.

AU - Mintun, Mark A.

AU - Arora, Anupa

AU - Joshi, Abhinay D.

AU - Lu, Ming

AU - Adler, Charles Howard

AU - Galasko, Douglas

AU - Liebsack, Carolyn

AU - Skovronsky, Daniel M.

AU - Sabbagh, Marwan N.

PY - 2014/4/9

Y1 - 2014/4/9

N2 - Background: Biomarkers based on the underlying pathology of Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB) have the potential to improve diagnosis and understanding of the substrate for cognitive impairment in these disorders. The objective of this study was to compare the patterns of amyloid and dopamine PET imaging in patients with AD, DLB and Parkinson's disease (PD) using the amyloid imaging agent florbetapir F 18 and 18F-AV-133 (florbenazine), a marker for vesicular monamine type 2 transporters (VMAT2).Methods: Patients with DLB and AD, Parkinson's disease (PD) and healthy controls (HC) were recruited for this study. On separate days, subjects received intravenous injections of florbetapir, and florbenazine. Amyloid burden and VMAT2 density were assessed quantitatively and by binary clinical interpretation. Imaging results for both tracers were compared across the four individual diagnostic groups and for combined groups based on underlying pathology (AD/DLB vs. PD/HC for amyloid burden and PD/DLB vs. AD/HC for VMAT binding) and correlated with measures of cognition and parkinsonism.Results: 11 DLB, 10 AD, 5 PD, and 5 controls participated in the study. Amyloid binding was significantly higher in the combined AD/DLB patient group (n = 21) compared to the PD/HC groups (n = 10, mean SUVr: 1.42 vs. 1.07; p = 0.0006). VMAT2 density was significantly lower in the PD/DLB group (n = 16) compared to the AD/ HC group (n = 15; 1.83 vs. 2.97; p < 0.0001). Within the DLB group, there was a significant correlation between cognitive performance and striatal florbenazine binding (r = 0.73; p = 0.011).Conclusions: The results of this study show significant differences in both florbetapir and florbenazine imaging that are consistent with expected pathology. In addition, VMAT density correlated significantly with cognitive impairment in DLB patients (ClinicalTrials.gov identifier: NCT00857506, registered March 5, 2009).

AB - Background: Biomarkers based on the underlying pathology of Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB) have the potential to improve diagnosis and understanding of the substrate for cognitive impairment in these disorders. The objective of this study was to compare the patterns of amyloid and dopamine PET imaging in patients with AD, DLB and Parkinson's disease (PD) using the amyloid imaging agent florbetapir F 18 and 18F-AV-133 (florbenazine), a marker for vesicular monamine type 2 transporters (VMAT2).Methods: Patients with DLB and AD, Parkinson's disease (PD) and healthy controls (HC) were recruited for this study. On separate days, subjects received intravenous injections of florbetapir, and florbenazine. Amyloid burden and VMAT2 density were assessed quantitatively and by binary clinical interpretation. Imaging results for both tracers were compared across the four individual diagnostic groups and for combined groups based on underlying pathology (AD/DLB vs. PD/HC for amyloid burden and PD/DLB vs. AD/HC for VMAT binding) and correlated with measures of cognition and parkinsonism.Results: 11 DLB, 10 AD, 5 PD, and 5 controls participated in the study. Amyloid binding was significantly higher in the combined AD/DLB patient group (n = 21) compared to the PD/HC groups (n = 10, mean SUVr: 1.42 vs. 1.07; p = 0.0006). VMAT2 density was significantly lower in the PD/DLB group (n = 16) compared to the AD/ HC group (n = 15; 1.83 vs. 2.97; p < 0.0001). Within the DLB group, there was a significant correlation between cognitive performance and striatal florbenazine binding (r = 0.73; p = 0.011).Conclusions: The results of this study show significant differences in both florbetapir and florbenazine imaging that are consistent with expected pathology. In addition, VMAT density correlated significantly with cognitive impairment in DLB patients (ClinicalTrials.gov identifier: NCT00857506, registered March 5, 2009).

KW - Alzheimer's disease

KW - Biomarkers

KW - Parkinson's disease

KW - PET imaging

UR - http://www.scopus.com/inward/record.url?scp=84901228427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901228427&partnerID=8YFLogxK

U2 - 10.1186/1471-2377-14-79

DO - 10.1186/1471-2377-14-79

M3 - Article

C2 - 24716655

AN - SCOPUS:84901228427

VL - 14

JO - BMC Neurology

JF - BMC Neurology

SN - 1471-2377

IS - 1

M1 - 79

ER -